Press Releases

SAN DIEGO, July 8, 2019 /PRNewswire/ -- More than 200,000 in-hospital cardiac arrests occur annually in the United States, with survival rates at less than 26%. Patients who suffer a cardiac arrest must receive the highest quality CPR possible, which is known to be the cornerstone for survival; however, certain

LYNDHURST, N.J., July 8, 2019 /PRNewswire/ -- CCA Industries, Inc. (OTC: "CAWW") announced today its results for the second quarter and six months ended May 31, 2019, which can be found in the table below.

JAMES E. WAGNER CULTIVATION CORPORATION HAS BEEN APPROVED FOR THE SALE OF CANNABIS OILS TORONTO, July 8, 2019 /PRNewswire/ - Canopy Rivers Inc. ("Canopy Rivers" or the "Company") (TSXV: RIV) (OTC: CNPOF) is pleased to share that its portfolio company, James E. Wagner Cultivation Corporation ("JWC") (TSXV: JWCA) (OTCQX:

HURLEYVILLE, N.Y., July 8, 2019 /PRNewswire/ -- On Thursday, July 4, 2019, The Center for Discovery (The Center) and its students and residen

AUSTIN, Texas, July 8, 2019 /PRNewswire/ -- Digital Pharmacist Inc. (www.digitalpharmacist.com), a rapidly growing software company that powers digital communication and adhere

LAS VEGAS, July 8, 2019 /PRNewswire/ -- As part of its commitment to address the addiction epidemic, the Voices Project is convening the first ever Mobilize Recovery conference i

LAKEWOOD, Colo., July 8, 2019 /PRNewswire/ -- In response to increased demand for its infusion services, Colorado-based Multispecialty Physician Partners ("MPP"), is announcing further expansion within the Dallas/Ft. Worth metroplex, designed to provide the additional capacity required for its antici

KING OF PRUSSIA, Pa., July 8, 2019 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that it will report results for its second quarter ended June 30, 2019 after the market closes on Thursday, July 25, 2019.  There will be a conference call for investors and analysts at

SOUTH SAN FRANCISCO, July 8, 2019 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc. ("Satsuma" or "the Company"), a late-stage biopharmaceutical company developing STS101, (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced that a poster describing pharmacokinetic (PK), safety and tolerability data from a Phase 1 trial of STS101

DUBLIN, July 8, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million.